Download PDF

1. Company Snapshot

1.a. Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.The company operates through three segments: Generics, Specialty, and AvKARE.The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.


The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas.It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism.The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.


It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers.The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.It operates in the United States, India, Ireland, and internationally.


The company was formerly known as Atlas Holdings, Inc.and changed its name to Amneal Pharmaceuticals, Inc.in 2018.


Amneal Pharmaceuticals, Inc.was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Show Full description

1.b. Last Insights on AMRX

Amneal Pharmaceuticals' recent performance was negatively impacted by a Q4 2024 earnings miss, with a quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago, indicating a decline in profitability. The company's weak Q4 earnings were a significant negative driver, overshadowing its strong 2024 financials, which saw revenues up 17% year-over-year.

1.c. Company Highlights

2. Amneal Pharmaceuticals' 2025 Earnings: A Strong Foundation for Future Growth

Amneal Pharmaceuticals, Inc. reported a robust financial performance for the fourth quarter and full year 2025, showcasing the strength of its diversified biopharmaceutical business. The company's revenue for 2025 grew 8% to $3 billion, while adjusted EBITDA increased 10% to $688 million. The adjusted EPS rose 43% to $0.83, beating analyst estimates. The actual EPS for the quarter came in at $0.21, relative to estimates of $0.18. The company's Affordable Medicines segment grew 4%, driven by an expanding portfolio of complex, differentiated, and durable products. The Specialty segment grew 19%, led by strong demand for Krexone, with over 23,000 patients on therapy and a market share of over 3%.

Publication Date: Mar -09

📋 Highlights
  • Strong 2025 Financial Growth:: Revenue rose 8% to $3 billion, adjusted EBITDA increased 10% to $688 million, and adjusted EPS surged 43% to $0.83.
  • Specialty Segment Expansion:: Grew 19% driven by Krexone, serving 23,000 patients with over 3% market share.
  • Biosimilars Progress:: Approved fourth and fifth products; targeting six U.S. biosimilars by 2027, with strong manufacturing partnerships like Pfizer’s GLP-1 collaboration.
  • 2026 Guidance:: Projects 1–4% revenue growth ($3.05–3.15 billion), 5–10% adjusted EBITDA growth, and 12–20% adjusted EPS growth.
  • AvKARE Performance:: Revenue jumped 12% to $745 million in 2025, with gross margin rising 41% to $147 million and operating income up 65% to $94 million.

Segment Performance

The Affordable Medicines segment is expected to continue growing, with 20 to 30 new product launches annually. The Specialty segment is also expected to drive growth, with Krexone achieving 3% market share and a gross-to-net ratio expected to be around 40% to 45%. The company's partnership with Pfizer on GLP-1s is progressing well, with a scalable and flexible manufacturing platform. Amneal received approval for its adenosine biosimilars, its fourth and fifth products, and remains on track to have six biosimilars in the U.S. market by 2027.

Guidance and Outlook

For 2026, Amneal expects top-line growth between 1% and 4%, adjusted EBITDA growth between 5% and 10%, and adjusted EPS growth between 12% and 20%. The company guides for total company revenue of $3.05 billion to $3.15 billion, with Affordable Medicines growing 7% to 8%, and Specialty revenues expected to be flat. Analysts estimate next year's revenue growth at 6.7%. The company's strong foundation and exciting strategic growth opportunities position it for sustained top and bottom-line growth.

Valuation and Leverage

Amneal reduced its net leverage to 3.5x and extended debt maturities to 2032, with a weighted average cost of debt of about 6.8% in 2026. The company's EV/EBITDA ratio stands at 10.92, indicating a reasonable valuation. The P/E Ratio is 57.58, suggesting that the market has priced in significant growth expectations. The company's Net Debt / EBITDA ratio is 4.02, indicating a manageable debt burden. With a strong pipeline and improving financials, Amneal is well-positioned for future growth.

3. NewsRoom

Card image cap

Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma

Apr -17

Source:

Card image cap

Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma

Apr -17

Source: proactiveinvestors.com

Card image cap

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

Apr -14

Source: globenewswire.com

Card image cap

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest

Apr -14

Source: defenseworld.net

Card image cap

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Apr -10

Source: zacks.com

Card image cap

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside

Apr -10

Source: zacks.com

Card image cap

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing

Apr -10

Source: zacks.com

Card image cap

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

Apr -09

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.10%)

6. Segments

Generics

Expected Growth: 5%

Amneal Pharmaceuticals' generics segment growth is driven by increasing demand for affordable medications, patent expirations of branded drugs, and strategic acquisitions. Additionally, the company's focus on vertical integration, cost savings, and investments in R&D and manufacturing capabilities have enabled it to capitalize on market opportunities, resulting in a 5% growth rate.

AvKARE

Expected Growth: 4%

AvKARE's 4% growth is driven by increasing demand for affordable generic medications, strategic partnerships, and expansion into new markets. Additionally, Amneal's vertical integration and cost-effective manufacturing capabilities enable AvKARE to offer competitive pricing, further fueling growth.

Specialty

Expected Growth: 7%

Amneal Pharmaceuticals' Specialty segment growth is driven by increasing demand for complex generics, successful product launches, and strategic partnerships. Additionally, the company's focus on niche therapeutic areas, such as CNS and infectious diseases, contributes to its growth. Furthermore, investments in R&D and manufacturing capabilities enable Amneal to capitalize on emerging opportunities in the specialty pharmaceutical market.

7. Detailed Products

Generic Pharmaceuticals

Amneal Pharmaceuticals offers a wide range of generic pharmaceuticals, including tablets, capsules, injectables, and ointments, covering various therapeutic areas such as cardiovascular, central nervous system, and infectious diseases.

Specialty Pharmaceuticals

Amneal's specialty pharmaceuticals segment focuses on complex and high-value products, including injectables, ophthalmics, and topical creams, targeting niche markets and underserved patient populations.

Biosimilars

Amneal's biosimilars segment develops and commercializes lower-cost, high-quality alternatives to branded biologics, offering affordable treatment options for patients with chronic diseases.

Over-the-Counter (OTC) Products

Amneal's OTC segment offers a range of consumer healthcare products, including pain relievers, allergy medications, and digestive health products.

Active Pharmaceutical Ingredients (APIs)

Amneal's API segment develops and supplies high-quality active pharmaceutical ingredients to pharmaceutical companies, enabling the production of finished dosage forms.

8. Amneal Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Amneal Pharmaceuticals, Inc. operates in a highly competitive industry with many substitutes available, but the company's focus on generic and specialty pharmaceuticals helps to mitigate this threat.

Bargaining Power Of Customers

Amneal Pharmaceuticals, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often essential to its customers, giving it an upper hand in negotiations.

Bargaining Power Of Suppliers

Amneal Pharmaceuticals, Inc. relies on a network of suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still exert some influence over prices and delivery terms.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This makes it difficult for new entrants to join the market.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. Amneal Pharmaceuticals, Inc. must continually innovate and invest in research and development to stay ahead of its competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 99.29%
Debt Cost 6.33%
Equity Weight 0.71%
Equity Cost 10.62%
WACC 6.36%
Leverage 13904.87%

11. Quality Control: Amneal Pharmaceuticals, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Intra-Cellular Therapies

A-Score: 5.3/10

Value: 6.0

Growth: 7.1

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Lantheus Holdings

A-Score: 4.9/10

Value: 4.0

Growth: 9.0

Quality: 8.0

Yield: 0.0

Momentum: 5.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Elanco Animal Health

A-Score: 4.4/10

Value: 2.7

Growth: 6.0

Quality: 3.9

Yield: 0.0

Momentum: 9.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Amneal Pharmaceuticals

A-Score: 4.2/10

Value: 4.0

Growth: 3.7

Quality: 3.4

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Deciphera Pharmaceuticals

A-Score: 4.0/10

Value: 6.2

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Catalent

A-Score: 2.7/10

Value: 3.1

Growth: 2.2

Quality: 2.2

Yield: 0.0

Momentum: 7.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

13.91$

Current Price

13.91$

Potential

-0.00%

Expected Cash-Flows